Business Context and Reporting Period
This Form 8-K filing by Tokai Pharmaceuticals, Inc. (noted as Eledon Pharmaceuticals in metadata) reports on the Annual Meeting of Stockholders held on June 15, 2016. The document details the voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The filing serves to disclose the outcome of shareholder votes rather than financial variances.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future operations or risks. It strictly reports the procedural results of the Annual Meeting.
Important Facts for Investors to Verify
- Director Election Results: Timothy J. Barberich received 15,763,569 votes "For" and 218,981 "Withheld." David A. Kessler, M.D. received 15,117,453 votes "For" and 865,097 "Withheld."
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP with 17,795,235 votes "For" and only 7,901 votes "Against."
- Broker Non-Votes: There were 1,820,596 broker non-votes recorded for the director election proposals.
- Company Name Discrepancy: Verify the current legal name of the entity, as the metadata lists "Eledon Pharmaceuticals, Inc." while the filing header explicitly states "Tokai Pharmaceuticals, Inc."